ClinicalTrials.govpublic full text
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
head and neck cancer, head and neck squamous cell carcinoma, metastatic head and neck cancer, recurrent head and neck cancer, metastatic head-and-neck squamous-cell carcinoma, recurrent head and neck squamous cell carcinoma, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 902128
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.